Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

NICE reversed its earlier decision on sparsentan for treating primary immunoglobulin A nephropathy after additional evidence ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

Panelists discuss how disease-modifying therapies for immunoglobulin A (IgA) nephropathy, though initially more expensive than symptomatic treatments, offer substantial long-term cost benefits by ...

Panelists discuss how early diagnosis of immunoglobulin A (IgA) nephropathy enables timely interventions that can ...

The US Food and Drug Administration (FDA) has accepted Otsuka Pharmaceutical’s biologics licence application for ...

The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in the NHS in ...